

Supplemental data



Table S1. Allograft survival risk factors univariable analysis.

Variables	With BK virus nephritis			Without BK virus nephritis		
	HR	IC 95%	<i>p</i> -value	HR	IC 95%	<i>p</i> -value
Recipient characteristics						
Female	0.80	0.49–1.33	0.39	0.80	0.47–1.37	0.42
Age at transplantation	1.01	0.99–1.03	0.31	1.01	0.99–1.03	0.20
Dialysis	1.73	0.63–4.75	0.29	2.03	0.64–6.50	0.23
Hemodialysis	1.29	0.64–2.60	0.48	1.47	0.67–3.24	0.34
CMV+	1.15	0.60–2.20	0.66	1.23	0.60–2.50	0.57
HCV+	1.55	0.71–3.40	0.27	1.82	0.82–4.00	0.14
HIV+	0.67	0.16–2.72	0.57	0.76	0.18–3.11	0.70
Initial nephropathy						
Hypertension	1.15	0.55–2.41	0.71	1.33	0.63–2.79	0.46
Unknown origin	0.83	0.44–1.59	0.58	0.78	0.38–1.58	0.48
Diabetes	1.66	0.93–2.95	0.08	1.51	0.80–2.85	0.20
Genetic	0.50	0.21–1.15	0.10	0.57	0.25–1.33	0.19
Glomerulopathy	1.23	0.73–2.08	0.43	1.11	0.63–1.98	0.71
Tubular and interstitial	1.01	0.37–2.77	0.99	1.18	0.43–3.25	0.75
Urologic	0.68	0.21–2.16	0.51	0.80	0.25–2.56	0.71
Other	0.56	0.08–4.01	0.56	0.68	0.09–4.94	0.71
Diabetes before transplant	1.66	0.96–2.86	0.07	1.60	0.89–2.88	0.12
Diabetes after transplant	1.55	0.70–3.47	0.28	1.49	0.63–3.54	0.37
Donor characteristics						
Age	1.02	1.01–1.04	0.004	1.02	1.01–1.04	0.008
Expanded Criteria Donor	1.74	1.07–2.81	0.02	1.54	0.92–2.57	0.10
eGFR	1.00	0.99–1.00	0.63	1.00	0.99–1.01	0.95
Living donor	1.05	0.45–2.42	0.91	1.24	0.53–2.88	0.62
CMV+	1.72	1.04–2.85	0.03	1.86	1.07–3.20	0.03
Sensitization risk factors						
Anti HLA antibodies	1.01	0.63–1.63	0.96	0.98	0.59–1.63	0.93
Former kidney transplantation	0.62	0.20–1.98	0.42	0.72	0.22–2.29	0.57
Donor specific anti-HLA antibodies	1.63	0.87–3.06	0.13	1.79	0.92–3.46	0.09
Combined Transplants						
Pancreas	0.73	0.10–5.24	0.75	0.84	0.12–6.04	0.86
Liver	0.94	0.23–3.82	0.93	1.08	0.26–4.43	0.91
Heart	*	*	*	*	*	*
Kidney Transplant Characteristics						
Cold ischemia time	1.03	0.99–1.06	0.04	1.03	0.99–1.07	0.11
Induction Immunosuppressive regimen	1.00	0.31–3.20	0.99	0.89	0.28–2.85	0.84
Basiliximab	0.85	0.53–1.37	0.51	0.86	0.51–1.43	0.55
Antithymocyte globulin	1.17	0.73–1.89	0.51	1.14	0.68–1.90	0.62
Intravenous Immunoglobulin	0.85	0.42–1.72	0.66	0.76	0.35–1.68	0.57
Rituximab	1.36	0.62–2.98	0.44	1.39	0.59–3.23	0.45
Maintenance immunosuppressive regimen						
Calcineurin inhibitors	*	*	*	*	*	*
Mycophenolate Mofetil	*	*	*	*	*	*
Steroids	*	*	*	*	*	*
Belatacept	*	*	*	*	*	*
White blood cells at the time of transplant						
Leucocytes (/1000)	0.97	0.87–1.09	0.64	0.95	0.84–1.07	0.66

Neutrophils (/1000)	1.00	0.89–1.13	0.96	0.97	0.85–1.11	0.70
Lymphocytes (/1000)	0.66	0.43–1.00	0.05	0.69	0.44–1.07	0.10
TCD4 cells (/1000)	0.17	0.06–0.51	0.001	0.18	0.06–0.59	0.004
TCD4 cells (%)	0.97	0.95–0.99	0.005	0.98	0.95–1.00	0.02
TCD8 cells (/1000)	0.47	0.15–1.54	0.21	0.52	0.14–1.85	0.31
TCD8 cells (%)	1.01	0.99–1.03	0.22	1.01	0.99–1.03	0.27
Follow up						
Opportunistic infection (OI) episode	3.04	1.65–5.61	0.0004	1.09	0.39–3.02	0.87
CMV viremia before OI	1.40	0.84–2.32	0.20	1.51	0.88–2.58	0.13
BK viruria before OI	1.41	0.83–2.39	0.21	*	*	*
BK viremia before OI	3.04	1.65–5.61	0.0004	*	*	*
BK virus nephritis	7.90	3.86–16.19	<0.0001	*	*	*
Acute rejection before OI	3.54	2.18–5.76	<0.0001	4.11	2.44–6.93	<0.0001